JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on EyePoint Pharmaceuticals today and set a price target of $41.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee has given her Buy rating due to a combination of factors related to EyePoint Pharmaceuticals’ competitive positioning and product reliability. The analyst highlights that while a competitor, 4DMT, has shown promising results in a small trial for diabetic macular edema, there are concerns about the long-term efficacy and the need for additional treatments. In contrast, EyePoint’s product, Duravyu, has demonstrated a more consistent performance in keeping patients free from rescue treatments over a longer period.
Chatterjee emphasizes that the expectation of redosing is already integrated into the treatment plans for EyePoint’s product, making it more reliable and easier to manage within clinical practices. This reliability and ease of administration are likely to make Duravyu a preferred choice among healthcare providers, supporting the Buy rating. The analyst’s confidence in EyePoint’s product is further bolstered by its potential to serve as a backbone therapy in retina practices, adding to its attractiveness as an investment.
According to TipRanks, Chatterjee is a 5-star analyst with an average return of 23.0% and a 62.69% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Tvardi Therapeutics, Opus Genetics, and KalVista Pharmaceuticals.
In another report released on July 30, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.